Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
111 Inc (YI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: YI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.3% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 60.07M USD | Price to earnings Ratio - | 1Y Target Price 5.96 |
Price to earnings Ratio - | 1Y Target Price 5.96 | ||
Volume (30-day avg) - | Beta 0.48 | 52 Weeks Range 4.14 - 12.90 | Updated Date 06/29/2025 |
52 Weeks Range 4.14 - 12.90 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.17 |
Earnings Date
Report Date 2025-06-19 | When - | Estimate - | Actual -0.2802 |
Profitability
Profit Margin -0.48% | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -0.03% | Return on Equity (TTM) -7.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19534374 | Price to Sales(TTM) - |
Enterprise Value 19534374 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA 37.4 | Shares Outstanding 5067440 | Shares Floating 70009558 |
Shares Outstanding 5067440 | Shares Floating 70009558 | ||
Percent Insiders 15.84 | Percent Institutions 23.69 |
Upturn AI SWOT
111 Inc
Company Overview
History and Background
111, Inc. was founded in 2010 and is headquartered in Shanghai, China. It operates as an integrated online and offline healthcare platform in China, connecting pharmaceutical companies with pharmacies and patients. It has evolved from an online pharmacy to a broader digital healthcare ecosystem.
Core Business Areas
- B2B Platform (1 Drug Mall): Provides a comprehensive pharmaceutical distribution platform connecting pharmaceutical companies and pharmacies.
- Retail Pharmacy Network (1 Drugstore): Operates a network of retail pharmacies offering prescription and OTC drugs, as well as other healthcare products.
- Online Healthcare Services: Offers online consultation, electronic prescriptions, and chronic disease management services to patients.
Leadership and Structure
The leadership team is composed of Yu Gang (Co-Founder & Executive Chairman) and Junling Liu (Co-Founder & CEO). The organizational structure includes various departments focused on supply chain, technology, marketing, and finance.
Top Products and Market Share
Key Offerings
- Pharmaceutical Products: Includes a wide range of prescription and over-the-counter (OTC) drugs. Market share data specifically for 111 Inc is difficult to obtain due to the fragmented nature of the Chinese pharmaceutical market. Competitors include Alibaba Health and JD Health.
- Healthcare Products: Encompasses medical devices, nutritional supplements, and personal care products. Market share data is similarly hard to pinpoint. Competitors include Pinduoduo, and traditional pharmacies.
- Online Consultation and E-prescriptions: Provides virtual healthcare services via its platform. Revenue from this segment is growing but specific figures are not publicly available. Competitors include Ping An Good Doctor.
Market Dynamics
Industry Overview
The Chinese pharmaceutical market is experiencing rapid growth, driven by an aging population, increasing healthcare awareness, and supportive government policies. E-commerce is playing an increasingly important role in the distribution of pharmaceutical products.
Positioning
111 Inc. positions itself as a leading integrated online and offline healthcare platform in China, leveraging technology to improve healthcare access and efficiency. It competes with larger players but differentiates itself through its integrated approach.
Total Addressable Market (TAM)
The Chinese healthcare market is estimated to be in the trillions of USD. 111 Inc aims to capture a significant portion of this TAM by expanding its online and offline presence and offering a comprehensive range of healthcare services.
Upturn SWOT Analysis
Strengths
- Integrated online and offline platform
- Extensive pharmacy network
- Strong relationships with pharmaceutical companies
- Growing online healthcare services
Weaknesses
- Limited brand recognition compared to larger players
- Reliance on regulatory approvals in China
- Profitability challenges
- Geographic concentration in certain regions of China
Opportunities
- Expanding into underserved markets in China
- Increasing adoption of online healthcare services
- Partnerships with hospitals and clinics
- Developing new value-added services
Threats
- Intense competition from established players
- Changing regulatory landscape in China
- Economic slowdown in China
- Data security and privacy concerns
Competitors and Market Share
Key Competitors
- ALBABA (BABA)
- JD Health (9618.HK)
- Ping An Good Doctor (1833.HK)
Competitive Landscape
111 Inc. faces intense competition from larger players with greater resources and brand recognition. Its integrated online and offline approach and focus on specific market segments offer some competitive advantages.
Growth Trajectory and Initiatives
Historical Growth: 111 Inc. has experienced significant revenue growth in recent years, driven by the expansion of its online and offline platforms.
Future Projections: Analyst estimates suggest continued revenue growth but profitability remains a key challenge. Future growth depends on successful execution of strategic initiatives.
Recent Initiatives: Recent initiatives include expanding its pharmacy network, launching new online healthcare services, and strengthening its supply chain capabilities.
Summary
111 Inc. is a growing player in the Chinese digital healthcare market, showing strong revenue growth but struggling with profitability. Its integrated online and offline approach is a key strength, but it faces intense competition and regulatory challenges. Future success hinges on its ability to scale efficiently and navigate the evolving regulatory landscape. Management should focus on cost reduction and achieving profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
- News Articles
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change. Market share percentages are estimates based on available resources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 111 Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-09-12 | Co-Founder, Acting CFO, Chairman & CEO Mr. Junling Liu | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 1238 | Website https://corporate.111.com.cn |
Full time employees 1238 | Website https://corporate.111.com.cn | ||
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates in two segments, B2C and B2B. The company offers supply chain integration services that help pharmaceutical companies manage products through online and offline channels; product promotion, customer analytics, patient education, and brand awareness services; and marketing and channel data services. It also provides 1 Pharmacy online wholesale pharmacy that offers pharmaceutical and other health and wellness products; and 1 Medicine Marketplace online retail pharmacy that provides pharmaceutical products and other merchandise. In addition, the company offers online loan application services; cloud-based inventory management services; smart procurement services, which collect pharmacies' historical purchase orders and inventory data; and Hawkeye automated salesforce tool. Further, it provides drugs, including prescription and over-the-counter drugs comprising Western and Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices that consists of bandages and thermometers; and personal care products that include skin care, birth control, sexual wellness, and baby products. Additionally, the company offers research and development, and consulting services; warehousing, procurement, and logistics services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.